Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria

被引：7
作者：
Arizpe, Andre [1 ]
Reveles, Kelly R. [1 ,2 ]
Patel, Shrina D. [3 ]
Aitken, Samuel L. [3 ,4 ]
机构：
[1] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA
[3] Univ Texas MD Anderson Canc Ctr, Div Pharm, 1515 Holcombe Blvd,Unit 0090, Houston, TX 77030 USA
[4] UTHlth McGovern Sch Med, Ctr Antimicrobial Resistance & Microbial Genom, Houston, TX 77030 USA
来源：
CURRENT INFECTIOUS DISEASE REPORTS | 2016年 / 18卷 / 12期
关键词：
Extended-spectrum beta-lactamase; Pseudomonas aeruginosa; Cefepime; Piperacillin-tazobactam; Carbapenem; Ceftolozane-tazobactam; Ceftazidime-avibactam; SPECTRUM-BETA-LACTAMASE; BLOOD-STREAM INFECTIONS; CEFTAZIDIME-AVIBACTAM ACTIVITY; US MEDICAL-CENTERS; IN-VITRO ACTIVITY; PSEUDOMONAS-AERUGINOSA INFECTION; URINARY-TRACT-INFECTIONS; EXTENDED-SPECTRUM; ESCHERICHIA-COLI; PIPERACILLIN-TAZOBACTAM;
D O I：
10.1007/s11908-016-0552-7
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Resistance to cephalosporins is now common among Gram-negative bacterial infections, including those caused by the Enterobacteriaceae and Pseudomonas aeruginosa, posing a major threat to public health. As resistance to the traditional drugs of choice for these infections, carbapenems, has also become increasingly common, interest in cefepime and piperacillin-tazobactam as carbapenemsparing alternatives has increased. Additionally, the availability of the novel beta-lactam-beta-lactamase inhibitor combinations ceftolozane-tazobactam and ceftazidime-avibactam has added to the antimicrobial armamentarium available to treat these multidrug-resistant infections. Here, we review the recent literature on the use of carbapenem-sparing alternatives and highlight the potential utility of novel antimicrobials.
引用
收藏
页数：12
相关论文
共 102 条
  • [1] High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center
    Aitken, Samuel L.
    Tarrand, Jeffrey J.
    Deshpande, Lalitagauri M.
    Tverdek, Frank P.
    Jones, Anne L.
    Shelburne, Samuel A.
    Prince, Randall A.
    Bhatti, Micah M.
    Rolston, Kenneth V. I.
    Jones, Ronald N.
    Castanheira, Mariana
    Chemaly, Roy F.
    [J]. CLINICAL INFECTIOUS DISEASES, 2016, 63 (07) : 954 - 958
  • [2] Use of Ceftolozane/Tazobactam in the Treatment of Multidrug-resistant Pseudomonas aeruginosa Bloodstream Infection in a Pediatric Leukemia Patient
    Aitken, Samuel L.
    Kontoyiannis, Dimitrios P.
    DePombo, April M.
    Bhatti, Micah M.
    Tverdek, Frank P.
    Gettys, Suzanne C.
    Nicolau, David P.
    Nunez, Cesar A.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (09) : 1040 - 1042
  • [3] Treatment of Extended-Spectrum Beta-Lactamase Enterobacteriaceae With Cefepime: The Dose Matters, Too
    Altshuler, Jerry
    Aitken, Samuel L.
    Guervil, David
    Esaian, Diana
    Papadopoulos, John
    Arias, Cesar A.
    [J]. CLINICAL INFECTIOUS DISEASES, 2013, 57 (06) : 915 - 916
  • [4] Secular Trends in Nosocomial Bloodstream Infections: Antibiotic-Resistant Bacteria Increase the Total Burden of Infection
    Ammerlaan, H. S. M.
    Harbarth, S.
    Buiting, A. G. M.
    Crook, D. W.
    Fitzpatrick, F.
    Hanberger, H.
    Herwaldt, L. A.
    van Keulen, P. H. J.
    Kluytmans, J. A. J. W.
    Kola, A.
    Kuchenbecker, R. S.
    Lingaas, E.
    Meessen, N.
    Morris-Downes, M. M.
    Pottinger, J. M.
    Rohner, P.
    dos Santos, R. P.
    Seifert, H.
    Wisplinghoff, H.
    Ziesing, S.
    Walker, A. S.
    Bonten, M. J. M.
    [J]. CLINICAL INFECTIOUS DISEASES, 2013, 56 (06) : 798 - 805
  • [5] Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms
    Bhat, Sunil V.
    Peleg, Anton Y.
    Lodise, Thomas P., Jr.
    Shutt, Kathleen A.
    Capitano, Blair
    Potoski, Brian A.
    Paterson, David L.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (12) : 4390 - 4395
  • [6] n Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy
    Bremmer, Derek N.
    Nicolau, David P.
    Burcham, Pam
    Chunduri, Anil
    Shidham, Ganesh
    Bauer, Karri A.
    [J]. PHARMACOTHERAPY, 2016, 36 (05): : E30 - E33
  • [7] Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates
    Buehrle, Deanna J.
    Shields, Ryan K.
    Chen, Liang
    Hao, Binghua
    Press, Ellen G.
    Alkrouk, Ammar
    Potoski, Brian A.
    Kreiswirth, Barry N.
    Clancy, Cornelius J.
    Nguyen, M. Hong
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (05) : 3227 - 3231
  • [8] In Vivo Comparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms
    Bulik, Catharine C.
    Tessier, Pamela R.
    Keel, Rebecca A.
    Sutherland, Christina A.
    Nicolaua, David P.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (01) : 544 - 549
  • [9] Updated Functional Classification of β-Lactamases
    Bush, Karen
    Jacoby, George A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (03) : 969 - 976
  • [10] Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
    Carmeli, Yehuda
    Armstrong, Jon
    Laud, Peter J.
    Newell, Paul
    Stone, Greg
    Wardman, Angela
    Gasink, Leanne B.
    [J]. LANCET INFECTIOUS DISEASES, 2016, 16 (06) : 661 - 673
12345678910